Introduction
============

Over the last few years, the management of metastatic colorectal cancer (mCRC) has changed substantially thanks to the availability of two classes of biological drugs: anti-angiogenic drugs, such as bevacizumab, aflibercet, and regorafenib, and anti-epidermal growth factor receptor inhibitors, such as cetuximab and panitumumab.[@b1-cmar-10-5659] Although *RAS* mutations have consistently been associated with reduced overall survival (OS), progression-free survival (PFS), and higher treatment failure rates among mCRC patients treated with anti-epidermal growth factor receptor antibodies,[@b2-cmar-10-5659] no genetic or molecular markers for anti-angiogenic drugs have been found as yet. The discovery of such markers to predict or monitor the efficacy of B would help to identify patients who are more likely to benefit from therapy.

Bevacizumab (B) is a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), a critical angiogenic factor involved in both physiological and pathological conditions. Preclinical studies suggest that the alternation of proangiogenic factors may modulate sensitivity to anti-VEGF therapy and allow regrowth of tumor-associated vasculature.[@b3-cmar-10-5659] Previous studies assessed circulating levels of pro- and antiangiogenic factors at baseline and during therapy in relation to the B response in different types of tumors, with conflicting results. Baseline plasma levels of the soluble VEGF receptor 1 (sVEGFR-1), VEGF, placental-derived growth factor (PlGF), and IL-6 during treatment showed a significant correlation with outcome in patients with locally advanced rectal carcinoma.[@b4-cmar-10-5659] Basic fibroblast growth factor, PlGF, hepatocyte growth factor (HGF), stromal cell-derived factor 1 (SDF-1), and monocyte-chemotactic protein 3 were shown to increase prior to disease progression in mCRC patients.[@b5-cmar-10-5659],[@b6-cmar-10-5659] sVEGFR-2, thrombospondin-1 (TSP-1),[@b6-cmar-10-5659] and VEGF-D[@b7-cmar-10-5659] were also higher in progressive disease in this patient setting.

In contrast, high baseline epidermal growth factor (EGF) and macrophage-derived chemokine (MDC) expression but low levels of IL-6, IL-8, and IL-10 were observed in mCRC patients responding to therapy.[@b8-cmar-10-5659] Furthermore, Wallyn demonstrated that a significant decrease in the expression of a small proteoglycan, endocan was a good prognosis marker in patients with stage IIIB--IV non-small-cell lung cancer treated with B.[@b9-cmar-10-5659] In patients with ovarian cancer treated with B, high levels of angiopoietin-1 (Ang-1) and low levels of the angiopoietin receptor Tie2 were associated with better PFS.[@b10-cmar-10-5659] In advanced renal cell carcinoma, serum Ang-2 and hypoxia-inducible factor 1-alpha (HIF-1α) tumor levels were important markers of the efficacy of sunitinib, another antiangiogenic drug.[@b11-cmar-10-5659] However, none of these results has been consistently replicated across different studies and cancer types.[@b12-cmar-10-5659],[@b13-cmar-10-5659]

In an attempt to overcome some of the limitations of earlier investigations, we simultaneously assessed a series of cytokines and angiogenic factors with a multiplex ELISA in mCRC patients treated with B. We measured the levels of 22 angiogenesis-associated proteins (FGF-basic, HGF, sTIE-2, sVEGFR-1, sVEGFR-2, Ang-2, EGF, IL-6, IL-8, PlGF, VEGF-A, VEGF-C, VEGF-D, PDGF-bb, Ang-1, SDF-1α, MDC, galectin-1, TSP1, endocan, eNOS, and HIF-1α) at baseline and during treatment to investigate whether changes in their levels might be correlated with therapeutic efficacy and disease outcome.

Patients and methods
====================

Patient selection and treatment
-------------------------------

This study included patients enrolled in the ITACa clinical trial (NCT01878422).[@b14-cmar-10-5659] Of the 376, we taken in consideration 58 patients receiving first-line chemotherapy (CT) (FOLFOX4 or FOLFIRI) plus B for which peripheral blood samples were available. Additional details about the treatment regimen and clinical outcomes for ITACa trial have previously been reported.[@b14-cmar-10-5659] Written informed consent was obtained from each patient regarding the use of serum for this correlative analysis. All patients underwent evaluation of *RAS*, *BRAF,* and microsatellite instability (MSI) status during their routine molecular diagnostic characterization.

Patients were evaluated for response according to RECIST criteria version 1.1. Tumor responses were assessed every 8 weeks by imaging tools such as computed tomography. Responders included complete response and partial response. Nonresponders included stable disease and disease progression.

All subjects gave their informed consent for inclusion before they participated in the study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by Local Ethics Committee (Ethics Committee Area Vasta Romagna and IRST).

Plasma collection, handling, and storage
----------------------------------------

Venous blood was drawn into EDTA vacutainer tubes and immediately processed for serum at baseline and at the first evaluation (about 2 months after the start of treatment). The tubes were centrifuged at 2,500× *g* for 15 minutes. The top layer of serum was aliquoted into 2 mL fresh tubes and stored at −80°C until use. Blood samples were available for analysis at baseline for 58 patients and at the first clinical evaluation for 55 patients (95%). All data were collected in accordance with good clinical practice guidelines.

Biomarker assessments and methodology
-------------------------------------

Levels of all serum proteins were determined using a Bio-Plex 200 array reader based on Luminex X-Map Technology (Bio-Rad Laboratories Inc., Hercules, CA, USA). Angio-genesis-associated protein concentrations were assessed in duplicate using a 5-plex ELISA assay of FGFb, HGF, sTie2s, VEGFR-1, and sVEGFR-2, an 8-plex assay of Ang-2, EGF, IL-6, IL-8, PlGF, VEGFA, VEGFC, and VEGFD, a 2-duplex assay of Ang-1 and PDGFbb and SDF-1α/CXCL12 and MDC/CCL22, and 5 singleplex ELISA assays of galectin-1, TSP-1, endocan, eNOS, and HIF-1α.

The protein concentrations (expressed as pg/mL or ng/mL) were calculated through a standard curve using the software provided by the manufacturer (Bio-Plex Manager Software v.6.1).

The assays were performed blinded to the study endpoint by Bioclarma Research and Molecular Diagnostics (Turin, Italy).

Statistical analyses
--------------------

The primary aim of the ITACa study was PFS, while secondary endpoints were OS and objective response rate (ORR). In the present work, we aimed to examine the association between 22 angiogenesis-associated proteins and PFS, OS, and ORR in the ITACa population and to investigate their variation during B treatment. The relationship between baseline serum proteins and clinical characteristics was analyzed using a nonparametric ranking statistic (median test). Logistic regression models and their 95% CIs, adjusted for baseline characteristics (gender, age, *RAS* status, tumor localization, and CT regimen) were used to evaluate the association between serum protein baseline levels and ORR (complete response + partial response). Covariate selection was based on a list of probable prognostic factors from the ITACa study.[@b14-cmar-10-5659] PFS was calculated as the time elapsed between the date of randomization and the date of first observation of progressive disease or the date of last tumor evaluation or the date of death in the absence of disease progression. OS was calculated as the time elapsed between the date of randomization and the date of death from any cause or the date of last follow-up. PFS and OS were estimated using the Kaplan--Meier method and were compared with the logrank test. 95% CIs were calculated by nonparametric methods. The Cox regression model was used to estimate HRs and their 95% CIs, adjusting for baseline characteristics. Baseline levels of serum proteins were dichotomized using the best cutoff determined by receiver-operating characteristic analysis at a median PFS. The median value of variation in the serum proteins from baseline to the first clinical evaluation was chosen as the cutoff point (20%). We conducted a landmark analysis to reduce potential confounding by time on treatment by assessing the impact of change in serum proteins form baseline to the first tumor evaluation (about 2 months after the start of treatment) on survival outcome. Patients who were still alive and had not been lost to followup at the landmark time were divided into two categories on the basis of whether they had progressed or not by that time. PFS and OS after the landmark time were computed with Kaplan--Meier curves. All *P*-values were based on two-sided testing, and statistical analyses were carried out using SAS statistical software version 9.4 (SAS Institute, Cary, NC, USA). Adjustments for multiple comparisons were not made, given the exploratory nature of the study.

Results
=======

Patient characteristics
-----------------------

The clinical pathological characteristics of patients are shown in [Table 1](#t1-cmar-10-5659){ref-type="table"}. Median age was 65 (37--83) years. Median PFS and OS were 12.1 months (95% CI 9.2--14.7) and 25.2 months (95% CI 17.8--34.5), respectively. Median follow-up was 64 months (range 2--79). A total of 31 (53%) patients were *RAS* mutated, while 7 (15%) were *BRAF* mutated. Twenty-eight patients had microsatellite stable tumors, one had a low MSI tumor and only four had high MSI disease.

Serum proteins at baseline
--------------------------

We evaluated the correlation between the main clinical pathological characteristics of patients and median baseline biomarker levels, observing a higher median baseline FGF level in right-sided tumors than in left-sided ones (92.98 pg/mL \[range 38.55--199.07\] and 60.84 pg/mL \[range 17.43--93.76\], respectively) (*P*=0.002). No significant differences were observed between median baseline biomarker levels and *RAS* and *BRAF* status (data not shown). Moreover, although there were no significant correlations between MSI status and serum protein levels (data not shown), a higher frequency of MSI tumors was observed in patients with low levels of IL-8 and Ang-2.

Objective response rate
-----------------------

There were a total of 38 patients responders and 20 nonresponders. We observed a significant difference in median baseline biomarker levels between responders and nonresponders, in particular for VEGF-C, MDC, and EGF (2,311 pg/mL \[range 1,107--3468\] vs 1,871 pg/mL \[range 1,871--2,825\] \[*P*=0.001\]; 645 pg/mL \[range 161--1,154\] vs 424 pg/mL \[range 136--1,170\] \[*P*=0.033\] and 196 pg/mL \[range 49--511\] vs 132 pg/mL \[range 40--388\] \[*P*=0.018\], respectively). Higher response rates were seen in patients with baseline VEGF-C, MDC, and EGF levels higher than the median value (adjusted odds ratio \[OR\]=13.05, 95% CI 2.73--62.22 \[*P*=0.001\]; OR=3.63, 95% CI 1.08--13.33 \[*P*=0.031\]; and OR=4.68, 95% CI 1.24--17.66 \[*P*=0.023\], respectively) ([Table 2](#t2-cmar-10-5659){ref-type="table"}). No significant differences were observed between other baseline biomarkers and ORR (data not shown).

PFS and OS
----------

Baseline IL-8 levels were correlated with PFS and OS; in particular, patients with ≥145 pg/mL IL-8 showed a shorter median PFS and OS than those with lower levels (6.5 vs 12.6 months, HR 7.39, 95% CI 2.76--19.83 \[*P*\<0.0001\] and 8.7 vs 28.8 months, HR 7.68, 95% CI 2.59--22.77 \[*P*\<0.001\], respectively) ([Figure 1](#f1-cmar-10-5659){ref-type="fig"} and [Table 3](#t3-cmar-10-5659){ref-type="table"}). Moreover, patients with ≥12,000 ng/mL TSP-1 levels showed a better median OS than those with lower levels (34.5 vs 13.1 months, HR 0.41, 95% CI 0.20--0.85 \[*P*=0.016\]) ([Figure 1](#f1-cmar-10-5659){ref-type="fig"} and [Table 3](#t3-cmar-10-5659){ref-type="table"}). Baseline Ang-2 levels showed borderline significance with PFS and OS. Patients with ≥1,740 pg/mL Ang-2 levels showed a shorter median PFS and OS than those with lower levels (9.0 vs 12.5 months, HR 1.99, 95% CI 0.89--4.45 \[*P*=0.096\] and 14.4 vs 28.8 months, HR 2.56, 95% CI 1.07--6.12 \[*P*=0.035\], respectively). No significant differences were observed between other biomarkers at baseline and PFS and OS (data not shown).

Serum protein modulation during therapy
---------------------------------------

We analyzed the variation in serum proteins from baseline to the first clinical evaluation. With regard to ORR, it was seen that patients with ≥20% reduction in Ang-2 levels had a higher ORR than those with a lower reduction (adjusted OR=4.29, 95% CI 1.13--16.31, *P*=0.003). A borderline significance was also observed for IL-8 modulation; in particular, patients with ≥20% reduction in IL-8 levels showed a higher ORR than those showing a lower reduction (adjusted OR=2.89, 95% CI 0.91--9.2, *P*=0.073).

We also evaluated PFS and OS in relation to serum bio-marker changes observed between baseline and the first clinical evaluation. Patients with a ≥20% reduction (N=36) in IL-8 levels showed a better median PFS and OS than those with a \<20% reduction (N=10) or an increase (N=9) (12.8 vs 9.1 months, HR 0.41, 95% CI 0.22--0.77, *P*=0.005 and 31.7 vs 19.3 months, HR 0.43, 95% CI 0.23--0.79, *P*=0.007, respectively). [Figure 2](#f2-cmar-10-5659){ref-type="fig"} shows the Kaplan--Meier curves for PFS and OS with respect to the reduction in IL-8 level between baseline and the first clinical evaluation. Patients with a ≥20% reduction in IL-6 levels had a better median PFS than those with \<20% reduction or an increase (14.0 months, 95% CI 9.0--25.1 vs 10.1 months, 95% CI 6.8--13.1, HR 0.56, 95% CI 0.32--0.99) (*P*=0.046). Moreover, patients with a ≥50% reduction in VEGF-C levels between baseline and the first clinical evaluation showed a shorter PFS compared with those with \<50% reduction (6.9 months, 95% CI 2.9--9.2 vs 12.5 months, 95% CI 9.6--14.9, HR 3.99, 95% CI 0.32--0.99) (*P*=0.046). There was no significant difference between the modulation of other biomarkers and clinical outcome (data not shown).

Discussion
==========

In the present study, we investigated the role of several angiogenesis-associated proteins and cytokines, evaluated at baseline and during B treatment, with respect to clinical outcome.

Our findings showed that low baseline IL-8 and high TSP-1 levels were associated with better clinical outcome, and that a \>20% reduction in IL-8 levels between baseline and the first evaluation was associated with better PFS and OS. In agreement with our results, di Salvatore et al observed that B-treated mCRC patients with low rather than high IL-8 levels had significantly longer median PFS and OS.[@b15-cmar-10-5659] Of note, they also found that the IL-8 single-nucleotide polymorphism c.-251 "A" allele was associated with significantly shorter PFS and OS. Given that this allele would appear to be correlated with variations in promoter transcriptional activity and higher levels of circulating IL-8,[@b16-cmar-10-5659]--[@b18-cmar-10-5659] their data support the hypothesis that patients carrying the A allele may benefit less from B because of higher IL-8 serum levels.

A number of authors have published similar results on the role of IL-8 in mCRC patients receiving B.[@b5-cmar-10-5659],[@b8-cmar-10-5659] Abajo et al reported a better clinical outcome when IL-8 baseline levels were lower,[@b8-cmar-10-5659] while Kopetz et al observed that elevated IL-8 at baseline was associated with a shorter PFS.[@b5-cmar-10-5659] We found that lower baseline IL-8 serum levels were associated with better PFS and OS. IL-8 is believed to promote migration, invasion, and in vivo angiogenesis by stimulating endothelial cell proliferation in response to hypoxia,[@b19-cmar-10-5659]--[@b22-cmar-10-5659] suggesting a possible role in tumor resistance.

With regard to TSP-1 in CRC, high tissue levels have been shown to correlate with higher survival rates.[@b23-cmar-10-5659] Moreover, Loupakis et al evaluated plasma levels of several angiogenesis-related proteins at different time points in a cohort of 25 patients undergoing CT+ B, observing a significant increase in TSP-1 levels when the disease progressed.[@b6-cmar-10-5659] Within this context, Brostjan et al reported significant variations in TSP-1 plasma levels after treatment with B.[@b24-cmar-10-5659] Our data demonstrated that patients with higher baseline VEGF-C, MDC, and EGF levels also had a better clinical outcome.

In agreement with our results, Abajo et al reported that high serum levels of EGF and MDC were associated with higher response rates. MDC attracts and activates a variety of cell types and enhance the immune response.[@b25-cmar-10-5659] Accordingly, high baseline levels of MDC in our responding patients would seem to suggest a role in promoting an immune response by T-helper cell recruitment. Moreover, patients in our study showing a reduction in IL-6 levels had better PFS. Similarly, Abajo et al observed lower IL-6 levels in patients responding to therapy.

The better outcome observed in the subset of patients with lower IL-6 and IL-8 levels is in agreement with the role ascribed to these cytokines in colon cancer progression and angiogenesis.[@b26-cmar-10-5659],[@b27-cmar-10-5659] We also obtained interesting results for Ang-2; in particular, high baseline levels were associated with a poorer clinical outcome. Similar findings have been reported in the literature for other tumors, including CRC, treated with B-base therapy.[@b28-cmar-10-5659]--[@b32-cmar-10-5659]

We also assessed biomarker levels in relation to the main molecular features, *RAS*, *BRAF*, and MSI status, but no significant correlations were observed. However, all MSI-high patients (12%) showed low levels of IL-8 and Ang-2 at baseline. Pogue-Geile et al reported that CRC patients diagnosed with MSI-high tumors showed a significant survival benefit from the addition of bevacizumab compared with no benefit in patients without MSI.[@b33-cmar-10-5659] These results are in agreement with our own findings if we consider that lower levels of IL-6 and Ang2 were correlated with better survival.

Moreover, our previous study demonstrated a higher benefit from the addition of bevacizumab to CT in right-sided tumors,[@b34-cmar-10-5659] in agreement with the CALGB/SWOG 80405 trial.[@b35-cmar-10-5659] Venook et al showed that bevacizumab significantly improved survival parameters in patients with right-sided lesions, while treatment with cetuximab improved PFS and OS in those with left-sided *KRAS* wild-type disease.[@b35-cmar-10-5659] In this context, it would be interesting to study serum biomarkers of response to bevacizumab, as evaluated in our study.

A limitation of our study is that we did not analyze the control arm receiving CT only. Thus, a clear distinction could not be made between the prognostic and predictive role of the serum biomarkers in relation to survival. Moreover, given the exploratory nature of the study, adjustments for multiple comparisons were not made. Overall, although our study is somewhat limited by its small sample size, the results were obtained on a (prospectively enrolled) patient population treated homogeneously in a randomized, prospective Phase III multicenter study (ITACa trial).[@b14-cmar-10-5659] An independent prospective study is ongoing to validate our results.

Conclusion
==========

Our results suggest that low baseline IL-8 levels and their reduction during B treatment and high baseline levels of TSP-1 may indicate better clinical outcome in mCRC patients treated with B. Our data, if confirmed in larger independent studies, would suggest a role of these angiogenic proteins in determining B efficacy.
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![Progression-free survival (PFS) and overall survival (OS) with respect to baseline IL-8 (**A** and **B**, respectively) and TSP-1 levels (**C** and **D**, respectively).\
**Notes:** ^a^Adjusted for chemotherapy regimen, gender, age, *RAS* status, and tumor localization.\
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![Progression-free survival (PFS) (**A**) and overall survival (OS) (**B**) with respect to reduction in IL-8 levels observed between baseline and first clinical evaluation.](cmar-10-5659Fig2){#f2-cmar-10-5659}

###### 

Patient characteristics (N=58)

  Patient characteristics         Total, N (%)
  ------------------------------- --------------
                                  
  **Median age, years (range**)   65 (37--83)
  **Gender**                      
  Male                            39 (67.2)
  Female                          19 (32.8)
  **Performance Status (ECOG)**   
  0                               51 (87.9)
  1--2                            7 (12.1)
  **Tumor localization**          
  Rectum                          17 (29.3)
  Colon                           41 (70.7)
  Right-sided                     25 (44.6)
  Left-sided                      31 (55.4)
  Unknown/missing                 2
  **Stage at diagnosis**          
  I--III                          14 (24.1)
  IV                              44 (75.9)
  **Grade**                       
  1+2                             31 (62.0)
  3                               19 (38.0)
  Unknown/missing                 8
  **CT regimen**                  
  FOLFOX4                         37 (63.8)
  FOLFIRI                         21 (36.2)
  ***RAS* status**                
  Wild type                       27 (46.6)
  Mutated                         31 (53.4)
  ***BRAF* status**               
  Wild type                       51 (87.9)
  Mutated                         7 (12.1)
  **MSI status**                  
  Stable-low instability          29 (87.9)
  High instability                4 (12.1)
  Unknown/missing                 25
  **Prior cancer therapy**        
  Surgery                         44 (75.9)
  Radiotherapy                    5 (8.6)
  Adjuvant chemotherapy           10 (17.2)

**Abbreviations:** CT, chemotherapy; ECOG, Eastern Cooperative Oncology Group; FOLFIRI, folinic acid, fluorouracil and irinotecan; FOLFOX, folinic acid fluorouracil and oxaliplatin; MSI, microsatellite instability.

###### 

Correlation between serum proteins and overall response rate

  Baseline serum protein levels (pg/mL)   CR/PR (N=38)   SD/PD (N=20)   OR (95% CI)[a](#tfn2-cmar-10-5659){ref-type="table-fn"}   *P*-value[a](#tfn2-cmar-10-5659){ref-type="table-fn"}
  --------------------------------------- -------------- -------------- --------------------------------------------------------- -------------------------------------------------------
                                                                                                                                  
  **VEGF-C**                                                                                                                      
  \<2,128                                 13 (44.8)      16 (55.2)      1.00                                                      
  ≥2,128                                  25 (86.2)      4 (13.8)       13.05 (2.73--62.22)                                       0.001
  **MDC**                                                                                                                         
  \<531                                   15 (51.7)      14 (48.3)      1.00                                                      
  ≥531                                    23 (79.3)      6 (20.7)       3.63 (1.08--13.33)                                        0.031
  **EGF**                                                                                                                         
  \<179                                   15 (51.7)      14 (48.3)      1.00                                                      
  ≥179                                    23 (79.3)      6 (20.7)       4.68 (1.24--17.66)                                        0.023

**Notes:**

Adjusted for chemotherapy regimen, gender, age, *RAS* status, and tumor localization.

**Abbreviations:** CR, complete response; EGF, epidermal growth factor; MDC, macrophage-derived chemokine; PD, progressive disease; PR, partial response; SD, stable disease; VEGF, vascular endothelial growth factor.

###### 

Progression-free and overall survival with respect to baseline serum protein levels

  Baseline serum protein levels   No. of patients   No. of events   Median value (95% CI)   HR[a](#tfn5-cmar-10-5659){ref-type="table-fn"} (95% CI)   *P*-value[a](#tfn5-cmar-10-5659){ref-type="table-fn"}   No. of events   Median value (95% CI)   HR[a](#tfn5-cmar-10-5659){ref-type="table-fn"} (95% CI)   *P-*value[a](#tfn5-cmar-10-5659){ref-type="table-fn"}
  ------------------------------- ----------------- --------------- ----------------------- --------------------------------------------------------- ------------------------------------------------------- --------------- ----------------------- --------------------------------------------------------- -------------------------------------------------------
                                                                                                                                                                                                                                                                                                                
  **IL-8**                                                                                                                                                                                                                                                                                                      
   \<145                          52                48              12.6 (9.6--15.4)        1.00                                                                                                              42              28.8 (21.4--36.7)       1.00                                                      
   ≥145                           6                 6               6.5 (1.9--9.7)          7.39 (2.76--19.83)                                        \<0.0001                                                5               8.7 (4.7--14.4)         7.68 (2.59--22.77)                                        \<0.001
  **TSP-1**                                                                                                                                                                                                                                                                                                     
   \<12,000                       18                17              9.2 (5.0--12.2)         1.00                                                                                                              17              13.1 (9.0--22.7)        1.00                                                      
   ≥12,000                        40                37              12.9 (9.6--15.9)        0.62 (0.32--1.20)                                         0.160                                                   30              34.5 (21.0--44.4)       0.41 (0.20--0.85)                                         0.016

**Notes:** IL-8 measured in pg/mL; TSP-1 measured in ng/mL;

Adjusted for chemotherapy regimen, gender, age, *RAS* status, and tumor localization.

**Abbreviation:** TSP, thrombospondin.
